{
}
AbbVie Inc. focuses on developing therapeutic drugs for various conditions, including rheumatoid arthritis, psoriasis, and HIV. The company generates 77.1% of its net sales from the United States, with other significant contributions from Germany, Canada, and Japan, among others. UBS has issued a neutral rating for the company.
AbbVie’s price target has been increased to $200 from $195 by UBS, reflecting a positive outlook on the company's performance. This adjustment highlights the confidence in AbbVie's growth potential in the market.
AbbVie Inc. has raised its full-year profit forecast, driven by strong demand for its leading anti-inflammatory drugs, Rinvoq and Skyrizi. The company now anticipates adjusted earnings between $10.90 and $10.94 per share, an increase from its previous guidance of $10.87.
The Nasdaq Composite reached a new high, with notable stock movements including a 1.2% rise for Microsoft and a 27% increase for Meta Platforms over the past three months. Advanced Micro Devices saw a 7% drop in after-hours trading despite a strong earnings report, while Eli Lilly and other pharma companies are set to report soon. Homebuilders are struggling, with the SPDR S&P Homebuilders ETF down 8.6% since mid-October, reflecting rising yields impacting the sector.
The bile duct cancer market is expanding, driven by a shortage of specialists and healthcare system challenges in developing countries. In 2021, North America led the market with a 37.1% share and $185.4 billion in revenue, fueled by increased R&D and rising cancer prevalence. The Asia-Pacific region is projected to grow the fastest through 2030, supported by awareness programs and private investments.
The third-quarter earnings season for major drugmakers, including Pfizer, Eli Lilly, AbbVie, Merck, and Bristol Myers Squibb, is underway, with Pfizer expected to report results on Oct. 29. Pfizer has consistently exceeded earnings expectations, with a four-quarter average surprise of 69.82%, despite declining COVID product sales. Overall, the Medical sector anticipates a 3.5% year-over-year earnings increase and an 8.8% revenue growth.
AbbVie has agreed to acquire Aliada Therapeutics for $1.4 billion, gaining access to innovative drug delivery technology aimed at overcoming the blood-brain barrier and a clinical-stage Alzheimer’s treatment, ALIA-1758. This move aligns with AbbVie’s focus on neuroscience, enhancing its capabilities in developing therapies for neurological disorders. The deal is expected to close by year-end and reflects a strategic investment in a sector facing challenges but also potential breakthroughs.
GSK is investing $800 million to expand its manufacturing site in Marietta, Pennsylvania, focusing on sterile liquid vaccines and drug substances, with operations expected by 2027 and 2028. Amgen has set a list price of $1,665 for its Eylea biosimilar, Pavblu, launching without a legal settlement, which may lead to penalties if future rulings favor Regeneron. Meanwhile, Roche has partnered with Dyno Therapeutics for gene therapy advancements, and AbbVie is collaborating with Gideon Richter on neuropsychiatric treatments. Marinus Pharmaceuticals is laying off staff after its seizure drug ganaxolone failed to meet Phase 3 study goals.
VHT and XLV are two prominent ETFs in the healthcare sector, with VHT managing $18.20 billion and XLV $41.08 billion in assets. VHT boasts a 1.39% yield and a strong performance, gaining 19.6% over the past year, while XLV offers a 1.50% yield and has risen 18.2% in the same period. Both funds have received an overall rating of A, indicating strong buy potential, with VHT ranked #2 and XLV ranked #1 among 42 ETFs in their category.
The Janus Henderson Biotech Innovation Fund leads biopharma hedge funds with a 39.35% year-to-date gain, despite a less than 1% rise in September. Other funds like Casdin Capital and Averill Partners also performed well, while EcoR1 Capital faced significant losses, down 11.4% for the year.
AbbVie Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
abbvie inc receives neutral rating as it focuses on diverse therapeutic drugs
00:58 01.11.2024
AbbVie price target increased to 200 by UBS analysts
15:14 31.10.2024
abbVie raises profit forecast as rinvoq and skyrizi exceed expectations
12:41 30.10.2024
market movers stocks to watch as earnings reports approach
Armenian Dram
D.R. Horton, Inc.
Advanced Micro Devices, Inc.
PulteGroup, Inc.
Biogen Inc.
AbbVie Inc.
Amgen Inc.
Lennar Corporation
GSK
Eli Lilly and Company
Meta Platforms, Inc.
KB Home
Toll Brothers, Inc.
Microsoft Corporation
Caterpillar Inc.
USA
Lisa Su
Jim Cramer
D.R. Horton
Show more
01:30 30.10.2024
global bile duct cancer market analysis and growth prospects through 2030
United States Dollar
Glaxosmithkline plc
Pfizer Inc.
Novartis AG
Fresenius Kabi AG
AbbVie Inc.
RUS
GBR
ITA
ESP
USA
KOR
SAU
JPN
MEX
ARE
ZAF
BRA
ARG
CHN
QAT
AUS
IND
DEU
CAN
Eli Lilly
GlaxoSmithKline plc
Pfizer Inc.
Novartis AG
AbbVie Inc.
Show more
22:25 28.10.2024
drug stocks poised for earnings surprises in third quarter results
United States Dollar
Pfizer Inc.
Eli Lilly and Company
Bristol-Myers Squibb Company
AbbVie Inc.
Merck & Co., Inc.
USA
Eli Lilly
Pfizer Inc.
Bristol Myers Squibb
Merck & Co.
AbbVie Inc.
Show more
17:06 28.10.2024
abbvie acquires aliada therapeutics for 1.4 billion to enhance neuroscience portfolio
United States Dollar
Landos Biopharma Inc.
Hoffmann-La Roche AG
Johnson & Johnson
Bristol-Myers Squibb Company
Biogen Inc.
AbbVie Inc.
Cerevel Therapeutics Holdings Inc.
Denali Therapeutics Inc.
Celsius Therapeutics
ImmunoGen Inc.
Eisai Co., Ltd.
USA
Roopal Thakkar
Paul Matteis
Show more
17:05 28.10.2024
gsk invests 800 million in us manufacturing amgen launches eylea biosimilar
United States Dollar
Hoffmann-La Roche AG
AbbVie Inc.
Amgen Inc.
Glaxosmithkline Export Ltd.
Marinus Pharmaceuticals, Inc.
USA
Ned Pagliarulo
Brian Abrahams
Jonathan Gardner
Jacob Bell
Show more
16:35 25.10.2024
healthcare etfs show strong performance and consistent dividend growth
Eli Lilly and Company
UnitedHealth Group Incorporated
Johnson & Johnson
AbbVie Inc.
USA
Rajkumari Saxena
Show more
23:30 24.10.2024
biotech hedge funds show mixed results as janus henderson leads the pack
Revolution Medicines, Inc.
Amicus Therapeutics, Inc.
Sarepta Therapeutics, Inc.
BioLife Solutions, Inc.
AbbVie Inc.
Andy Acker
Dan Lyons
Joe Biden
Show more
17:35 23.10.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People: